Bolni Marius Nagalo, PhD, MSc

Research Program: Cancer Therapeutics Faculty Rank: Assistant Professor Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Pathology Research

Cancer Research Interest

• Disease Site Focus: GI, Breast, Gynecology, Prostate, Thyroid, Multiple Myeloma
• Research Focus Area: Treatment, Health Disparities
• Type of Research: Basic, Clinical
• Research Interest Statement: My research interests include translational virotherapy for patients with advanced hepatocellular carcinoma (HCC), gene therapy hepatobiliary and pancreatic cancers, and addressing health disparities in liver cancer, cancer therapy, and cancer-focused research. Before joining UAMS, I received numerous honors during my training and career to date, including a Mentored Research Scientist Career Development Award (K01) from the National Institutes of Health/National Cancer Institute in 2018, the Welcome Trust Mobility and Skills Training Award from Cardiff University in 2018, and the Kathryn H. and Roger Penske Career Development Award at Mayo Clinic’s Arizona Campus in 2019. All of these sponsors allowed me to establish the basis of an independent research program focused on the development of precision therapeutics to treat advanced unmet clinical need human cancers.

Contact Information

• Email Address: BMNAGALO@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• NIH/Nat. Cancer Institute – 1DP2CA301099
  “Exploring Strategies to Enhance Drug Delivery and Tumor Immunogenicity in Pancreatic Cancer.”
  Principal Investigator
  9/1/2024 – 8/31/2027
• American Association for Cancer Research – NA
  “Development of a New Virotherapy Platform to treat Pancreatic Cancer”
  Principal Investigator
  7/1/2022 – 6/30/2025

Recent Publications

• Eslinger C, Uson PLS Jr, Nagalo BM, Borad MJ. Spontaneous regression of advanced hepatocellular carcinoma following COVID-19 infection and vaccination: a case report and review of literature. Journal of gastrointestinal oncology. 2024 15(4):1933-1938. PMID: 39279952. PMCID: PMC11399873.
• Albadawi H, Zhang Z, Keum H, [et al., including Nagalo BM]. Percutaneous Delivery of Oncogel for Targeted Liver Tumor Ablation and Controlled Release of Therapeutics. Advanced materials (Deerfield Beach, Fla.). 2024:e2406080. PMID: 39148179. PMCID: PMC11543513.
• Ferdous KU, Tesfay MZ, Cios A, [et al., including Nagalo BM]. Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer. Biomedicines. 2024 12(7). PMID: 39062169. PMCID: PMC11275208.
• Bazie MM, Sanou M, Djigma FW, [et al., including Nagalo BM]. Genetic diversity and occult hepatitis B infection in Africa: A comprehensive review. World journal of hepatology. 2024 16(5):843-859. PMID: 38818293. PMCID: PMC11135261.
• Boateng ST, Roy T, Agbo ME, [et al., including Nagalo BM]. Multifaceted approach toward mapping out the anticancer properties of small molecules via in vitro evaluation on melanoma and nonmelanoma skin cancer cells, and in silico target fishing. Chemical biology & drug design. 2024 103(1):e14418. PMID: 38230791.
• Hartupee C, Nagalo BM, Chabu CY, [et al.]. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Frontiers in immunology. 2024 15:1287459. PMID: 38361931. PMCID: PMC10867137.
• Boateng ST, Roy T, Torrey K, [et al., including Nagalo BM]. Synthesis, in silico modelling, and in vitro biological evaluation of substituted pyrazole derivatives as potential anti-skin cancer, anti-tyrosinase, and antioxidant agents. Journal of enzyme inhibition and medicinal chemistry. 2023 38(1):2205042. PMID: 37184042. PMCID: PMC10187093.
• Marin LP, Presley JH, Noori K, [et al., including Nagalo BM]. Partnership in Cancer Research (PCAR) Program Increases Medical Student Knowledge and Confidence to Perform Cancer Research. Journal of cancer education : the official journal of the American Association for Cancer Education. 2023. PMID: 37957501. PMCID: PMC10995089.
• Watters CR, Barro O, Elliott NM, [et al., including Nagalo BM]. Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma. Molecular therapy oncolytics. 2023 29:4-14. PMID: 36969560. PMCID: PMC10033453.
• Zongo SV, Djigma FW, Yonli AT, [et al., including Nagalo BM]. Association of DRB1*11 and DRB1*12 alleles of the HLA system with the evolution of the Hepatitis B virus infection in Burkina Faso. Molecular biology reports. 2023. PMID: 37101005.
• Nagalo BM, Zhou Y, Loeuillard EJ, [et al.]. Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology (Baltimore, Md.). 2022. PMID: 36052732.
• Uson Junior PLS, Majeed U, Yin J, [et al., including Nagalo B]. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO precision oncology. 2022 6(1):e2100274. PMID: 35666960. PMCID: PMC9200394.
• Roy T, Banang-Mbeumi S, Boateng ST, [et al., including Nagalo BM]. Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation. Frontiers in immunology. 2022 13:1075804. PMID: 36741386. PMCID: PMC9889994.
• Zhang Y, Nagalo BM. Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?. Frontiers in immunology. 2022 13:898631. PMID: 35837384. PMCID: PMC9273848.
• Zhang Y, Gabere M, Taylor MA, [et al., including Nagalo BM]. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Frontiers in oncology. 2022 12:1042250. PMID: 36457491. PMCID: PMC9706410.
• Baker AT, Nagalo M, Boyd RJ, [et al.]. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science advances. 2021 7(49):eabl8213. PMID: 34851659. PMCID: PMC8635433.
• Uson Junior PLS, Nagalo M, DeLeon TT, [et al.]. FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Digestive diseases and sciences. 2021. PMID: 34773565.
• Arora M, Nagalo M, Bogenberger JM, [et al.]. Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. Hepatology (Baltimore, Md.). 2021. PMID: 34407567.
• Uson Junior PLS, Nagalo BM, Ahn DH, [et al.]. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. Seminars in liver disease. 2021 41(2):136-141. PMID: 33957697.
• Roy T, Boateng ST, Banang-Mbeumi S, [et al., including Nagalo BM]. Identification of new fisetin analogs as kinase inhibitors: Data on synthesis and anti-skin cancer activities evaluation. Data in brief. 2021 35:106858. PMID: 33665254. PMCID: PMC7907707.
• Wongjarupong N, Oli S, Sanou M, [et al., including Nagalo BM]. Distribution and Incidence of Blood-Borne Infection among Blood Donors from Regional Transfusion Centers in Burkina Faso: A Comprehensive Study. The American journal of tropical medicine and hygiene. 2021. PMID: 33617474. PMCID: PMC8045619.
• Roy T, Boateng ST, Banang-Mbeumi S, [et al., including Nagalo BM]. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers. Bioorganic chemistry. 2021 107:104595. PMID: 33450548. PMCID: PMC7870562.
• Wongjarupong N, Yonli AT, Nagalo BM, [et al.]. Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Hepatology communications. 2020 4(12):1781-1792. PMID: 33305149. PMCID: PMC7706297.
• Nagalo BM, Breton CA, Zhou Y, [et al.]. Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. Molecular therapy oncolytics. 2020 18:546-555. PMID: 32839735. PMCID: PMC7437509.
• Arora M, Bogenberger JM, Abdelrahman A, [et al., including Nagalo BM]. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer chemotherapy and pharmacology. 2020 85(6):1063-1078. PMID: 32440762.
• Bayala B, Coulibaly AY, Djigma FW, [et al., including Nagalo BM]. Chemical composition, antioxidant, anti-inflammatory and antiproliferative activities of the essential oil of Cymbopogon nardus, a plant used in traditional medicine. Biomolecular concepts. 2020 11(1):86-96. PMID: 32304294.
• Bayala B, Coulibaly AY, Djigma FW, [et al., including Nagalo BM]. Chemical composition, antioxidant, anti-inflammatory and antiproliferative activities of the essential oil of Cymbopogon nardus, a plant used in traditional medicine. Biomolecular concepts. 2020 11(1):86-96. PMID: 34233420.
• Sombié HK, Sorgho AP, Kologo JK, [et al., including Nagalo BM]. Glutathione S-transferase M1 and T1 genes deletion polymorphisms and risk of developing essential hypertension: a case-control study in Burkina Faso population (West Africa). BMC medical genetics. 2020 21(1):55. PMID: 32188413. PMCID: PMC7081581.
• Sorgho PA, Djigma FW, Martinson JJ, [et al., including Nagalo BM]. Role of Killer cell immunoglobulin-like receptors (KIR) genes in stages of HIV-1 infection among patients from Burkina Faso. Biomolecular concepts. 2019 10(1):226-236. PMID: 31863692.